Pharmaceutical industry in India

Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index

Retrieved on: 
Thursday, December 14, 2023
Health, Environment, Sustainability, Clinical Trials, Pharmaceutical, Biotechnology, NYSE, Ethics, Climate, Labour, DJSI, Standard, Patient, Innovation management, Dow Jones, ISO, Nature, BSE, Agroforestry, Pharmaceutical industry in India, GRI, United Nations Global Compact, Human rights, WEF, NSE, RDY, Access, Sustainable procurement, ESG, Circularity, Health care

Reddy’s”), a global pharmaceutical company, has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance (ESG) agenda.

Key Points: 
  • Reddy’s”), a global pharmaceutical company, has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance (ESG) agenda.
  • Dr. Reddy’s has become the first Indian pharma company to earn a place in the Standard & Poor Dow Jones Sustainability World Index (DJSI World) for 2023.
  • Alongside its debut in DJSI World, the company retains its place in the Dow Jones Sustainability Index for Emerging Markets (DJSI EM) for the 8th year in a row.
  • The DJSI recognitions are based on Dr. Reddy’s performance in the Standard & Poor Global Corporate Sustainability Assessment (S&P Global CSA) and additional screening criteria.

IPS Appoints Jim Stephanou as New CEO

Retrieved on: 
Monday, June 5, 2023
Research, Architecture, Professional Services, Pharmaceutical, Commercial Building & Real Estate, Construction & Property, Science, Engineering, Biotechnology, Building Systems, Health, Consulting, Manufacturing, Pharmaceutical industry, Multimedia, Drexel University, Berkshire, Bayer Corporation, Pleasure, Growth, Merck, Merck & Co., Pharmaceutical industry in India, IPS, Management

View the full release here: https://www.businesswire.com/news/home/20230605005759/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230605005759/en/
    IPS is excited to announce the appointment of Jim Stephanou as its new Chief Executive Officer (CEO) to lead the company into its next phase of growth.
  • Before joining Merck, Mr. Stephanou held several leadership positions at Bayer Corporation and Lyondell Basell Industries for over two decades.
  • Mr. Stephanou will report to Dave Goswami, the Global CEO of IPS Enterprise.
  • When discussing the new CEO appointment for IPS Life Science, Mr. Goswami stated, “We are excited to have someone of Jim’s caliber to take on the CEO role.

The National Medical Products Administration (NMPA) issues product license for Abiraterone acetate 250 mg, Bioequivalance study conducted in India by Accutest Research Laboratories (I) Pvt. Ltd., one of the Top Indian CRO

Retrieved on: 
Monday, September 6, 2021
Health care, Health, Pharmaceutical industry, Pharmaceuticals policy, Abiraterone acetate, Antiestrogens, Pyridines, Contract research organization, Food and Drug Administration, Drugs Controller General of India, Pharmaceutical industry in India

BEIJING and MUMBAI, India, Sept. 6, 2021 /PRNewswire/ -- National Medical Products Administration (NMPA) China, announces the approval of Abiraterone acetate 250mg of Qilu Pharmaceuticals for marketing purpose.

Key Points: 
  • BEIJING and MUMBAI, India, Sept. 6, 2021 /PRNewswire/ -- National Medical Products Administration (NMPA) China, announces the approval of Abiraterone acetate 250mg of Qilu Pharmaceuticals for marketing purpose.
  • Applicable Bioequivalance studies for marketing authorization were conducted at Accutest Research Laboratories (I) Pvt.
  • Accutest is a Contract Research Organization (CRO) offering full range of services based in India.
  • An official from Clinical affairs department of Qilu Pharma said, "Thanks to Accutest Research Laboratories, we have successfully achieved our goal in the advance for the Abiraterone acetate projects.

Rafarma Signs Trilateral Investment Agreement Officially Launching Tashkent Pharmaceutical Plant Build

Retrieved on: 
Friday, July 30, 2021
Health care, Health, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Articles, Forward-looking statement, Pharmaceutical industry in India

Rafarma Pharmaceuticals previously announced its plans to build a scientific and pharmaceutical complex on the territory of Tashkent Pharma Park by the end of 2026.

Key Points: 
  • Rafarma Pharmaceuticals previously announced its plans to build a scientific and pharmaceutical complex on the territory of Tashkent Pharma Park by the end of 2026.
  • The trilateral agreement was signed July 24, 2020 by representatives of Rafarma Pharmaceuticals, the Agency for the Development of the Pharmaceutical Industry of Uzbekistan and the Directorate for the Development of the Innovative Scientific and Production Pharmaceutical Cluster Tashkent Pharma Park.
  • The total investment will amount to $85 million (US), work on the project commences this year.
  • Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934.

ZS Elects Pratap Khedkar to CEO

Retrieved on: 
Wednesday, July 28, 2021
Consulting, Other Professional Services, Professional services, ZS Associates, ZS, Pharmaceutical industry in India

Global professional services firm ZS today announced that Pratap Khedkar, head of the firms global biopharmaceuticals and healthcare ecosystem practices, has been elected to CEO by the firms leaders.

Key Points: 
  • Global professional services firm ZS today announced that Pratap Khedkar, head of the firms global biopharmaceuticals and healthcare ecosystem practices, has been elected to CEO by the firms leaders.
  • Khedkar has held various leadership roles during his 21 years with ZS.
  • Pratap is stepping into this role during an exciting period of growth and change at ZS, said Wright, who oversaw the companys 30% growth in 2020.
  • Chris has done a tremendous job during his tenure as CEO, and Ill be leaning on his knowledge and guidance in the months and years ahead, Khedkar said.

Global Pharmaceutical Contract Manufacturing Market Trajectory & Analytics to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Health, Pharmaceutical, Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Pharmaceutical industry in India, Pharmaceutical industry

The "Pharmaceutical Contract Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical Contract Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Pharmaceutical Contract Manufacturing estimated at US$100 Billion in the year 2020, is projected to reach a revised size of US$130.2 Billion by 2026, growing at a CAGR of 4.6% over the analysis period.
  • Growth in the global market is set to be driven by positive trends in the broader pharmaceuticals market which is in turn driven by growth in the emerging markets.
  • The U.S. Market is Estimated at $31.6 Billion in 2021, While China is Forecast to Reach $21.1 Billion by 2026
    The Pharmaceutical Contract Manufacturing market in the U.S. is estimated at US$31.6 Billion in the year 2021.

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

Retrieved on: 
Tuesday, July 13, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Health care, Health, Healthcare in India, Pharmaceutical industry in India, Pharmaceutical industry in China, Fiscal year

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2021.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2021.
  • No revenue was recognized for the fiscal year ended April 30, 2021, compared to $12.7 million for the prior fiscal year.
  • Research and development expenses were $41.3 million for the fiscal year ended April 30, 2021, compared to $40.2 million for the prior fiscal year.
  • On July 11, 2021, the Board of Directors adopted the KalVista Pharmaceuticals, Inc. 2021 Inducement Equity Incentive Plan (the Plan).

Acerus Provides Update on Litigation with Recipharm

Retrieved on: 
Monday, July 12, 2021
Pharmaceuticals policy, Health care, Health, Recipharm, Pharmaceutical industry in India, Pharmaceutical industry in China, Pharmac

TORONTO, July 12, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the Company or Acerus) (TSX:ASP, OTCQB:ASPCF) today announced that, on June 15, 2021, it prevailed at a preliminary issue trial in which Recipharm Limited (Recipharm) alleged that Acerus claim for damages was barred by the terms of the companies manufacturing contract.

Key Points: 
  • TORONTO, July 12, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the Company or Acerus) (TSX:ASP, OTCQB:ASPCF) today announced that, on June 15, 2021, it prevailed at a preliminary issue trial in which Recipharm Limited (Recipharm) alleged that Acerus claim for damages was barred by the terms of the companies manufacturing contract.
  • "This is an important step forward in Acerus effort to hold Recipharm accountable for its contractual breaches, said Ed Gudaitis, President and Chief Executive Officer of Acerus.
  • Manufacturers in the pharmaceutical industry rely on contract manufacturing organizations like Recipharm to ensure that patients have access to the medicines they need.
  • On June 18, 2020, Acerus announced it had commenced litigation against Recipharm, a wholly-owned subsidiary of Recipharm AB, in the Commercial Court of London.

FFF Enterprises Celebrates 33 Years of Helping Healthcare Care®

Retrieved on: 
Thursday, July 8, 2021
Life sciences, Health sciences, Health care, Healthcare in India, Pharmaceutical industry in India, Pharmaceutical industry in China, Biopharmaceutical

FFF Enterprises business models and innovations continue to evolve to ensure the safety and efficacy of the biopharmaceuticals marketplace.

Key Points: 
  • FFF Enterprises business models and innovations continue to evolve to ensure the safety and efficacy of the biopharmaceuticals marketplace.
  • With more than 33 years of experience in product allocation management, FFF Enterprises is dedicated to meeting the needs of our most precious patients.
  • Everything we do affirms our dedication to sustain a reliable, secure pharmaceutical supply chain in the pursuit of our mission of Helping Healthcare Care.
  • Please visit FFF Enterprises' news site , as well as LinkedIn , Instagram , Facebook and YouTube for more information about the company.

Moderna Vice President of US Manufacturing to Deliver Keynote Address at the 2021 ISPE Facilities of the Future Conference

Retrieved on: 
Thursday, July 8, 2021
Health sciences, Health care, Health, Pharmaceuticals policy, GxP, Medical research, Alexion Pharmaceuticals, Pharmaceutical industry in India, Pharmaceutical industry in China, Moderna COVID-19 vaccine, Moderna, Quality assurance

Nickerson joined Moderna in May 2016 as Head of Quality accountable for all aspects of GxP Quality.

Key Points: 
  • Nickerson joined Moderna in May 2016 as Head of Quality accountable for all aspects of GxP Quality.
  • Before Moderna, he was with Alexion Pharmaceuticals serving as Vice President of Quality Assurance and Quality Control.
  • The opening keynote session COVID's Impact on Pharma Facilities of the Future will take a high-level look ahead at global pharmaceutical manufacturing and related regulatory systems.
  • Nickerson will discuss the impact of COVID on the industry and the applications of future manufacturing operations.